Six hundred and fifteen centers from 45 countries reported a total 30 293 HSCT to this 2008 EBMT survey with 26 810 first transplants (40% allogeneic, 60% autologous). This corresponds to an increase of 7% for the allogeneic and 3% for the autologous HSCT. Main indications were leukemias (32%; 89% allogeneic); lymphomas (56%; 89% autologous); solid tumors (6%; 96% autologous); and non-malignant disorders (6%; 88% allogeneic). There were more unrelated than HLAidentical sibling donors (49 vs 46%). The proportion of peripheral blood transplants remained stable with 99% for autologous and 70% for allogeneic HSCT. One fifth of the teams with 480 HSCT performed more than half of all HSCT. This trend towards teams with higher numbers of HSCT was stronger for allogeneic (Gini coefficient 57%) than for autologous HSCT (Gini coefficient 38%). Transplant rates (number of transplants per 10 million inhabitants) increased in a close to linear way with increasing team density (number of transplant teams per 10 million inhabitants) and without saturation (R 2 ¼ 0.54); this connection was even stronger for allogeneic HSCT (R 2 ¼ 0.67). These data illustrate status and trends for HSCT in Europe. They provide a rational basis for planning and patient counseling.
Introduction
This 2008 activity report joins the past series of annual surveys of the European Group for Blood and Marrow Transplantation EBMT, which has become an important instrument to describe the status of hematopoietic SCT (HSCT) in Europe to observe trends and to monitor changes in technology use. [1] [2] [3] [4] It captures the numbers of HSCT in the preceding year from each participating team by indication, donor type and stem cell source. Thanks to the near 20-year history of the survey, its standardized structure over many years and the excellent commitment by the participating teams, observation of changes over the years and short to midterm predictions of trends have become possible. [5] [6] [7] The reports have given detailed annual numbers and have focused each year on one specific aspect such as stem cell source, donor type or a defined disease category. In recent years, the numbers of donor lymphocyte infusions were added. Since 2007, the survey collects in collaboration with sister organizations in Europe, information on other cellular therapies besides standard HSCT, such as mesenchymal stem cell therapies and HSCT for nonhematological indications.
Previous analyses indicated an impact of team size and team density on transplant rates and a high predictability of transplant rates 8 . Little distinction was made between donor types and disease classification. In addition, the ongoing discussions in several European countries on optimal use of infrastructure and on optimal numbers of HSCT per teams warrant data on the current situation. Therefore, our interest was for a more detailed analysis on the distribution of number of transplants by the participating teams and on the impact of team density on transplant rates of different disease indications. In addition, we tried to establish some short and mid-term predictions. 5 Key aspects of these findings are presented in this report.
Patients and methods

Data collection and validation
Participating teams were requested to report their data for 2008 by indication, stem cell source and donor type as listed in Table 1 and as in preceding years. Quality control measures included several independent systems: confirmation
Transplant numbers
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Transplant rates
Transplant rates, defined as numbers of HSCT per 10 million inhabitants, were computed for each country without adjustments for patients who crossed borders and received their HSCT in a foreign country. Population numbers were obtained from the US census office database (www.census.gov).
Team size and density
Team size was defined as the number of first HSCT for patients transplanted in the year 2008. Team size was analyzed separately for total HSCT, allogeneic or autologous HSCT only. Team density was defined as numbers of transplant teams per 10 million inhabitants and was computed for each country, for the total of all HSCT as well as separately for autologous and allogeneic HSCT.
Statistical analysis
The relation between transplant rates and team density is estimated by ordinary least squares and its explanatory content expressed by the coefficient of determination (R 2 ). Multiple regression analyses assess trends over time. The Gini coefficient 7 classifies the inequality among transplantation teams for different types of treatment with respect to the number of HSCT.
Results
Activity of participating teams
Of the 615 teams, 370 (60%) did both allogeneic and autologous transplants; 222 (36%) restricted their activity to autologous, 10 teams (2%) to allogeneic transplants. 13 teams (2%) reported having performed no transplants in 2008.
There was substantial variation in the number of HSCT performed by the participating institutions. Forty-seven teams (8% of all teams) reported 1-5 HSCT (0.3% of all HSCT), 143 teams (23%) 6-20 HSCT (6%), 201 teams (33%) 21-50 HSCT (22%), 145 teams (24%) 51-100 HSCT (34%), 58 teams (9%) 101-150 HSCT (23%) and 21 teams (3%) more than 150 HSCT (14%). Hence, it took typically around four small teams to match the average number of transplants that a large institution performed.
The 117 teams (roughly a fifth of all teams) with more than 80 HSCT performed over 50% of all transplants in 2008. Hence, the contribution of small teams and large teams to the total of all transplants was unequal with a higher contribution of larger teams as exemplified by the Lorenz curve in Figure 1 . If all teams would contribute equally, the coefficient would be zero and equal to the 45 1C curve. It is of interest to note that this inequality is nearly identical for allogeneic (Gini coefficient 45%) and autologous HSCT (Gini coefficient 44%) as for the total of HSCT (Gini coefficient 46%). Table 1 . Main indications were lymphoproliferative disorders with 15 127 patients (56%), 1699 patients with allogeneic HSCT (11%), 13 428 with autologous HSCT (89%); leukemias with 8610 patients (32%), 7632 (Table 1) . Highest increases in allogeneic HSCT were observed for patients with nonmalignant disorders ( þ 15%), specifically for BM failure syndromes ( þ 18%), hemoglobinopathies ( þ 18%) and inherited disorders of metabolism ( þ 43%). Above average increases for patients with malignancies were noted for AML beyond first CR ( þ 12%), myeloproliferative syndromes ( þ 22%), and chronic lymphocytic leukemia ( þ 14%). It is interesting to note that number of allogeneic HSCT for CML in the first chronic phase continued to decline and were for the first time ever lower than the numbers of allogeneic HSCT in the advanced phase, which continued to increase ( þ 2%). Overall, numbers of HSCT for CML decreased by 11%. Highest increases in autologous HSCT were observed for patients with leukemias ( þ 8%), specifically for ALL ( þ 19%) and AML ( þ 9%). Numbers increased on average for all lymphoproliferative disorders by about 3%, with the exception of non-myeloma plasma cell disorders (À22%). Numbers of autologous HSCT for solid tumors continued to decrease with the exception of neuroblastoma ( þ 15%) and germinal tumors ( þ 6%). Among the non-malignant disorders, numbers increased for autoimmune disorders by 9% (Table 1) .
Numbers of HSCT in 2008
Donor type and stem cell source Stem cell source in 2008. Of the 16 028 autologous first transplants, 200 (1%) were BM derived and 15 828 (99%) were derived from PBSCs or from combined peripheral blood and BM. There were no autologous HSCT reported for cord blood cells (Table 1) . Of the 10 782 allogeneic first transplants, 2445 (23%) were BM, 7631 (70%) were peripheral blood and 706 (7%) were cord blood transplants. This indicates that the trend from BM to peripheral blood as stem cell source for allogeneic HSCT has stabilized over the last 2 years (2006, 70% peripheral blood; 2007, 71% peripheral blood, 2008, 70% peripheral blood) . The proportion of peripheral blood as stem cell source increased from 68% for unrelated and twin donors to 73% for HLA-identical sibling donors and to 76% for other family member donors.
Stem cell source was influenced by main indication. BM remained the preferred source of stem cells for nonmalignant disorders (56%) with even a higher proportion of BW for HLA-identical sibling donor transplants (63%). In contrast, peripheral blood was the preferred choice for malignant disorders (Figure 2 ) with the highest proportion of peripheral blood for leukemias (79%, Table 1 ). Interestingly, the proportion was the same for patients with acute leukemia in first CR or with CML in first chronic phase as for patients with advanced leukemias. Overall, the proportion of peripheral blood has slightly decreased over the past years for malignant disease indications (Figure 2 ).
There were 706 first HSCT with cord blood in 2008, which corresponds to an increase of 21% from the 585 cord blood HSCT in 2007. Of these were 7% HLA-identical sibling cord blood HSCT, 0.2% other family donor cord blood HSCT and 93% unrelated cord blood HSCT. It is of interest to note that targeted cord blood HSCT (family donor HSCT) was almost exclusively used for nonmalignant disorders ( Figure 3 ). The proportion of unrelated donors compared with HLAidentical sibling donors differed from disease to disease with the highest in AML not in first CR, MDS and inherited disorders of metabolism and the lowest in hemoglobinopathies.
Use of reduced intensity conditioning in 2008
Numbers of RIC HSCT continued to increase from 3914 in 2007 to 4397 in 2008 at the same rate as allogeneic HSCT. RIC was used for 37% of all allogeneic HSCT, similar to that of last year's survey. This information is collected in a generic way only; no information on disease distribution is possible through the activity survey. Table 2 summarizes the use of additional cellular therapies in Europe. There were 357 mesenchymal stem cell transplants performed by 55 teams in 21 countries (Austria, Belgium, Finland, Germany, Greece, Iran, Israel, Italy, Lebanon, Luxembourg, Netherlands, Poland, Portugal, Russia, Serbia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom). Indications for these transplants were musculoskeletal, neurological, epithelial and autoimmune disorders. There were 454 HSCT for nonhematopoietic use by 31 teams in 13 countries. This includes 313 (69%) HSCT for cardiovascular disorders, 74 (16%) HSCT for neurological disorders, and 67 (15%) HSCT for tissue repair. These numbers represent a substantial increase from last year with 212 mesenchymal stem cell transplants and 212 HSCT for non-hematopoietic use in 2007.
Additional cellular therapies
Team density and transplant rates Transplant rates differed substantially between European countries and countries affiliated with the EBMT (Figure 4 ). These differences relate to all types of HSCT. Total transplant rates (Figure 4a ) in Europe ranged from 11 HSCT per 10 million inhabitants in the Ukraine to 848 (median: 293). As in previous years, the transplant rate was highest in Israel, a country that is known to accept patients across borders for HSCT. Transplant rates for allogeneic HSCT (Figure 4b ) ranged from 1 (several countries) to 496 in Israel (median: 72). They ranged from 2 (several countries) to 607 in Iceland (median: 215) for autologous HSCT (Figure 4c) .
Transplant rates were associated with World Bank Category and Gross National Income per Capita (data not shown). They were also associated with team density. There were 13 out of 47 participating countries with only one reporting transplant team. These countries either belonged to the low income World Bank Category or were countries with less than 3 million inhabitants. In the remaining countries, the number of transplant teams ranged from 1 to 107 in Germany (median: 5), with 1 to 65 allogeneic (median: 3) and 1 to 101 autologous transplant teams (median: 4.5).
Team density ranged from 0.2 (Ukraine) to 35.7 (Iceland) per 10 million inhabitants (median: 6.1) for all HSCT, from 0.2 (Ukraine) to 12.5 (Belgium, median: 4.2) for allogeneic, and from 0.2 (Ukraine) to 35.7 (Iceland, median: 6.1) for autologous HSCT.
The logarithm of transplant rates increased with increasing team density in a close to linear way (Figures 5) . Hence, an expansion of the number of teams by a fixed percentage raises the number of transplantation by a proportional growth factor with no clear indication for saturation. The explanatory content reached a level of R 2 ¼ 54% for both total HSCT (5a) and allogeneic HSCT (5b), and the connection was even stronger for autologous HSCT (R 2 ¼ 67%, Figure 5c ). A comparable pattern applies for AML allogeneic HSCT (R 2 ¼ 56%, Figure 5d ) and PCD autologous HSCT (R 2 ¼ 78%, Figure 5e ), the most frequent indications of the autologous and allogeneic subsample. The same figures for the data of 2002 reveal very similar patterns but steeper slopes of the regression equations. 9 The decline of these coefficients from roughly 1.0-1.2 to around 80-90% might serve as a first sign of saturation. However, no significant threshold value of the team density by which transplantation rates do not rise any more could be found.
Discussion
Data from this report describe the current state of art of HSCT in Europe in 2008. They document and confirm the ongoing role of autologous and allogeneic stem cells for a broad range of malignant and non-malignant disorders. 10 In addition, they show some novel and interesting trends.
These most recent data confirm the steady increase in allogeneic HSCT by 7% and in autologous HSCT by 3.5%. They show too that the increase is not the same for all indications. The increase in allogeneic HSCT is most marked for leukemias and non-malignant disorders, especially hemoglobinopathies and inborn errors of metabolism. This increase is clearly associated with the increasing availability of unrelated donors, including unrelated cord blood products, and with the clear indications for an allogeneic HSCT in defined situations of acute leukemias. [11] [12] [13] There are only two disease categories with a decline in allogeneic HSCT: solid tumors and chronic myeloid leukemia in first chronic phase. For the first time, there were more transplants in CML in advanced phases of the disease than in first chronic phase. This is somehow surprising in view of the fact that outcome of HSCT for CML is so clearly superior if the transplant is performed still in chronic phase and monitoring of the disease and failed response to imatinib can be captured in principle in time.
14,15 Information of the CML community relating to this fact appears warranted.
The increase in autologous HSCT is seen for acute leukemias and all types of lymphoproliferative disorders. This is somehow surprising and there is apparently no obvious trend yet to refrain from autologous HSCT despite the new modern drugs for patients with myeloma or lymphoma. 16 In contrast, autologous HSCT for solid tumors continues to decline, with the exception of the few entities with clear prospective randomized studies documenting an advantage for autologous HSCT compared with standard chemotherapy. Breast cancer, the leading indication a decade ago has almost become a non-entity. 17, 18 There were several interesting observations on changes and trends in the use of stem cell source. For autologous HSCT, peripheral blood remains almost the sole source of stem cells and no single autologous cord blood stem cell transplant was reported by the 615 participating teams. This observation clearly contrasts with the advertising activity of private cord blood banks but supports the EBMT guidelines on the use and storage of cord blood for private use. In contrast, cord blood continued to increase, at the same rate of plus 7% as allogeneic HSCT and with a proportion of about 7% of all allogeneic HSCT. There was a wide variation in the use of cord blood between the different participating countries, in absolute numbers, in transplant rates for cord blood or in the proportion of cord blood as source for an allogeneic HSCT. 19 Countries with lower cord blood rates had a higher transplant rate of other family member transplants, indicating a preference for haploidentical HSCT. Furthermore, the proportion of peripheral blood as stem cell source has slightly declined over the last few years. BM remains the preferred source for patients with non-malignant diseases. 20 This observation is explained by the clear advantage of BM as stem cell source in aplastic anemia, even though the still positive proportion of peripheral blood for this indication raises some concerns. The same holds true for the observation that the proportion of peripheral blood as stem cell source in malignant diseases was the same in early and advanced disease stage despite some indications that patients in early disease might profit more from BM.
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Team size or the number of procedures by a team in a given period has been intensively discussed, not only in the field of HSCT. Some studies indeed suggest that the annual number of procedures in a team might have an impact on outcome. This has been observed in HSCT, in organ transplantation and complex medical interventions.
22-27
The survey cannot give an answer on the correct number of HSCT per year. The data only show that the vast majority of transplants are performed in teams undertaking more than 50 HSCT per year. In smaller countries, a small team might provide the necessary infrastructure.
7 There is a clear association between team density, the number of teams per number of inhabitants and transplant rates. Patients need to have access to the procedure. So far, there is no indication for saturation, hence no indication that teams overuse their facilities. This applies to all HSCT as well as to the most frequent indications for allogeneic (AML) or autologous (PCD) HSCT. Compared with the first analysis in 2002, there are changes in the steepness of the correlation curve; this might be a first indication that in countries with very high team densities, saturation might be close. An optimal number of team density or team size cannot be given by the data. Still, assumptions can be made: one team per 1 million might be needed to provide optimal service; the overall contribution of the 190 teams with less than 20 HSCT per year is marginal with 6.3% of all HSCT.
For the first time, the survey collected data on the use of mesenchymal stromal cell therapies and on hematopoietic stem cells for non-hematopoietic indications. These data indicate a wide spread use. Main indications include cardiovascular regeneration, neurological disorders or tissue repair. These data have to be regarded with caution. Not all teams performing HSCT are in contact with their colleagues from other fields in medicine. More time is needed to establish a comprehensive survey on tissue engineering and regenerative medicine cellular therapies. The preliminary data from this survey should serve as a stimulus to do so.
In summary, the report 2008 describes the status of HSCT in Europe and gives a clear perspective for patient counseling and health care planning.
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